Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Opioid Use Disorder (OUD) Market, by Drug Class
1.4.2 Asia Pacific Opioid Use Disorder (OUD) Market, by Route of Administration
1.4.3 Asia Pacific Opioid Use Disorder (OUD) Market, by Distribution Channel
1.4.4 Asia Pacific Opioid Use Disorder (OUD) Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Opioid Use Disorder (OUD) Market
Chapter 4. Asia Pacific Opioid Use Disorder (OUD) Market by Drug Class
4.1 Asia Pacific Buprenorphine Market by Country
4.2 Asia Pacific Methadone Market by Country
4.3 Asia Pacific Naltrexone Market by Country
Chapter 5. Asia Pacific Opioid Use Disorder (OUD) Market by Route of Administration
5.1 Asia Pacific Parenteral Market by Country
5.2 Asia Pacific Oral Market by Country
Chapter 6. Asia Pacific Opioid Use Disorder (OUD) Market by Distribution Channel
6.1 Asia Pacific Hospital Pharmacies Market by Country
6.2 Asia Pacific Retail Pharmacies & Stores Market by Country
6.3 Asia Pacific Online Pharmacies Market by Country
Chapter 7. Asia Pacific Opioid Use Disorder (OUD) Market by Country
7.1 China Opioid Use Disorder (OUD) Market
7.1.1 China Opioid Use Disorder (OUD) Market by Drug Class
7.1.2 China Opioid Use Disorder (OUD) Market by Route of Administration
7.1.3 China Opioid Use Disorder (OUD) Market by Distribution Channel
7.2 Japan Opioid Use Disorder (OUD) Market
7.2.1 Japan Opioid Use Disorder (OUD) Market by Drug Class
7.2.2 Japan Opioid Use Disorder (OUD) Market by Route of Administration
7.2.3 Japan Opioid Use Disorder (OUD) Market by Distribution Channel
7.3 India Opioid Use Disorder (OUD) Market
7.3.1 India Opioid Use Disorder (OUD) Market by Drug Class
7.3.2 India Opioid Use Disorder (OUD) Market by Route of Administration
7.3.3 India Opioid Use Disorder (OUD) Market by Distribution Channel
7.4 South Korea Opioid Use Disorder (OUD) Market
7.4.1 South Korea Opioid Use Disorder (OUD) Market by Drug Class
7.4.2 South Korea Opioid Use Disorder (OUD) Market by Route of Administration
7.4.3 South Korea Opioid Use Disorder (OUD) Market by Distribution Channel
7.5 Singapore Opioid Use Disorder (OUD) Market
7.5.1 Singapore Opioid Use Disorder (OUD) Market by Drug Class
7.5.2 Singapore Opioid Use Disorder (OUD) Market by Route of Administration
7.5.3 Singapore Opioid Use Disorder (OUD) Market by Distribution Channel
7.6 Malaysia Opioid Use Disorder (OUD) Market
7.6.1 Malaysia Opioid Use Disorder (OUD) Market by Drug Class
7.6.2 Malaysia Opioid Use Disorder (OUD) Market by Route of Administration
7.6.3 Malaysia Opioid Use Disorder (OUD) Market by Distribution Channel
7.7 Rest of Asia Pacific Opioid Use Disorder (OUD) Market
7.7.1 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Drug Class
7.7.2 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Route of Administration
7.7.3 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Distribution Channel
Chapter 8. Company Profiles
8.1 Indivior PLC (Reckitt Benckiser Group plc)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Product and Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.3 Orexo AB (Orexo US, Inc.)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Alkermes PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Trials and Approvals:
8.5 Titan Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Trials and Approvals:
8.6 Camurus AB
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Trials and Approvals:
8.7 AstraZeneca PLC
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.8 Hikma Pharmaceuticals PLC
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Product Launches and Product Expansions:
8.9 Mallinckrodt PLC
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.10. Viatris, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental Analysis
8.10.4 Research & Development Expense
Unique Offerings 